His main research concerns Internal medicine, Gastroenterology, Infliximab, Surgery and Ulcerative colitis. His research links Placebo with Internal medicine. His Gastroenterology research is multidisciplinary, incorporating perspectives in Colonoscopy, Intestinal mucosa and Monoclonal antibody.
His study looks at the intersection of Infliximab and topics like Malignancy with Pooled analysis and Antibody. His Surgery research incorporates elements of Relative risk and Confidence interval. Gary R. Lichtenstein combines subjects such as Clinical endpoint, Adverse effect and Colitis with his study of Ulcerative colitis.
Gary R. Lichtenstein mainly investigates Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Surgery. In general Gastroenterology study, his work on Colitis often relates to the realm of MMX, thereby connecting several areas of interest.
The various areas that Gary R. Lichtenstein examines in his Ulcerative colitis study include Adverse effect, Tofacitinib, Clinical trial and Maintenance therapy. His Inflammatory bowel disease research is multidisciplinary, relying on both Azathioprine, Immunology and Intensive care medicine. Many of his studies on Crohn's disease apply to Certolizumab pegol as well.
His scientific interests lie mostly in Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology and In patient. His study ties his expertise on Oncology together with the subject of Internal medicine. His work investigates the relationship between Inflammatory bowel disease and topics such as Intensive care medicine that intersect with problems in MEDLINE and Guideline.
His Ulcerative colitis study is concerned with the larger field of Disease. Disease is closely attributed to Surgery in his study. The Gastroenterology study combines topics in areas such as Placebo and Chromoendoscopy.
Gary R. Lichtenstein focuses on Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology and Crohn's disease. Gary R. Lichtenstein performs integrative Internal medicine and In patient research in his work. His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Irritable bowel syndrome, Biosimilar, Intensive care medicine, Endoscopy and Depression.
His research in Ulcerative colitis intersects with topics in Mercaptopurine, Tofacitinib, Janus kinase inhibitor, Clinical trial and Retrospective cohort study. His Gastroenterology research includes elements of Vedolizumab and Placebo. His Crohn's disease research integrates issues from Pharmacy, Diabetes mellitus, Adult patients and Pulmonary disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)
Management of Crohn's Disease in Adults
Gary R Lichtenstein;Stephen B Hanauer;Stephen B Hanauer;Stephen B Hanauer;William J Sandborn;William J Sandborn;William J Sandborn.
The American Journal of Gastroenterology (2001)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Paul Rutgeerts;Brian G. Feagan;Gary R. Lichtenstein;Lloyd F. Mayer.
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Gary R. Lichtenstein;Brian G. Feagan;Russell D. Cohen;Bruce A. Salzberg.
Clinical Gastroenterology and Hepatology (2006)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frédéric Colombel;Paul Rutgeerts;Walter Reinisch;Dirk Esser.
ACG Clinical Guideline: Management of Crohn’s Disease in Adults
Gary R Lichtenstein;Edward V Loftus;Kim L Isaacs;Miguel D Regueiro.
The American Journal of Gastroenterology (2018)
Serious Infection and Mortality in Patients With Crohn ' s Disease: More Than 5 Years of Follow-Up in the TREAT ™ Registry
Gary R Lichtenstein;Brian G Feagan;Russell D Cohen;Bruce A Salzberg.
The American Journal of Gastroenterology (2012)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease
Gary R. Lichtenstein;Songkai Yan;Mohan Bala;Marion Blank.
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
Paul Rutgeerts;Robert H. Diamond;Mohan Bala;Allan Olson.
Gastrointestinal Endoscopy (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: